CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2, and inhibits class I/II HDACs, but not class III, Sir-type HDACs.

Quisinostat 2HCl is a novel second-generation HDAC inhibitor.

PCI-34051 is a potent and specific HDAC8 inhibitor.

Abexinostat is a broad-spectrum phenyl hydroxamic acid inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

RGFP966 is an HDAC3 inhibitor.

AR-42 is an HDAC inhibitor with IC50 of 30 nM.

Sodium butyrate, sodium salt of butyric acid, is a histone deacetylase inhibitor and competitively binds to the zinc sites of class I and II histone deacetylases (HDACs).